TIAPRIDE

/static/temp/default.svg

Search structure


Synonyms	NSC-758225 Tiapride
Status
Molecule Category	Free-form
ATC	N05AL03
UNII	LAH70H9JPH
EPA CompTox	DTXSID0023664


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	JTVPZMFULRWINT-UHFFFAOYSA-N
Smiles	CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC
InChI	InChI=1S/C15H24N2O4S/c1-5-17(6-2)10-9-16-15(18)13-11-12(22(4,19)20)7-8-14(13)21-3/h7-8,11H,5-6,9-10H2,1-4H3,(H,16,18)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C15H24N2O4S
Molecular Weight	328.43
AlogP	1.17
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	8.0
Polar Surface Area	75.71
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	22.0

Bioactivity

Mechanism of Action	Action	Reference
Dopamine D2 receptor antagonist	ANTAGONIST	Other PubMed PubMed


Protein: Dopamine D2 receptor Description: D(2) dopamine receptor Organism : Homo sapiens P14416 ENSG00000149295











Protein: Dopamine D3 receptor Description: D(3) dopamine receptor Organism : Homo sapiens P35462 ENSG00000151577

Assay Description	Organism	Bioactivity	Reference
DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912)	None	779.0 nM
DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone)	None	411.0 nM
DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone)	None	390.0 nM

Related Entries

Environmental Exposure

Environmental Exposure Map

Countries
Czech Republic
Germany
Hungary
Romania
Slovakia
Slovenia

Cross References

Resources	Reference
ChEBI	94666
ChEMBL	CHEMBL84158
DrugBank	DB13025
DrugCentral	2651
FDA SRS	LAH70H9JPH
Human Metabolome Database	HMDB0042039
PubChem	5467
SureChEMBL	SCHEMBL34750
ZINC	ZINC000001542927

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).